Clinical Trial Update: Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the Ranibizumab Port Delivery System for sustained delivery in subfoveal neovascular age-related macular degeneration; results complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab Port Delivery System (ranibizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2021-05-06